Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endothelium
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Delivery to the brain of drugs, peptides, and genes depends on the availability of brain‐specific delivery vectors. We used a phage‐displayed library of llama single‐domain antibodies (sdAbs) to enrich for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). Two sdAbs (FC5 and FC44) were selected, sequenced, subcloned, and expressed as fusion proteins with c‐Myc‐His 5 tags. Similar to phage‐displayed sdAbs, soluble FC5 and FC44 were shown to selectively bind HCEC and to transmigrate across an in vitro human blood‐brain barrier (BBB) model. Both FC5 and FC44, in contrast to an unrelated llama sdAb, were also detected in the brain after i.v. injection into mice. These small (~14 kDa) antibodies have characteristics essential for a carrier‐vector and can be used to facilitate drug transport across the BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Organ targeting In vivo using phage display peptide libraries
Pasqualini, R., & Ruoslahti, E. (1996) · Nature · doi:10.1038/380364a0 · Cited by 1,221
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
Antibody phage display technology and its applications
Hoogenboom, H. R., de Bruı̈ne, A. P., Hufton, S. E., Hoet, R. M., Arends, J.-W., & Roovers, R. C. (1998) · Immunotechnology · doi:10.1016/s1380-2933(98)00007-4 · Cited by 512
Delivery of peptides and proteins through the blood–brain barrier
Bickel, U., Yoshikawa, T., & Pardridge, W. M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00139-3 · Cited by 481
Transporting therapeutics across the blood-brain barrier
Abbott, N. J., & Romero, I. A. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88720-x · Cited by 447
Transferrin and Transferrin Receptor Function in Brain Barrier Systems
Moos, T., & Morgan, E. H. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006948027674 · Cited by 394
Pardridge, W. M. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199707000-00001 · Cited by 328
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“For their use in targeting drugs across the blood–brain barrier (BBB) into the brain, VHHs were selected that transmigrate the human BBB in an in vitro model and accumulate in the brain after intravenous injection into mice (Muruganandam et al. 2002).”
BackgroundApproaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology
Deli, M. A., Ábrahám, C. S., Kataoka, Y., & Niwa, M. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1377-8 · Cited by 643
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L., Law, K., Chen, Y., Wang, X., Jiang, Y., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.044 · Cited by 384
A guide to: generation and design of nanobodies
Muyldermans, S. (2021) · The FEBS Journal · doi:10.1111/febs.15515 · Cited by 352
Domain antibodies: proteins for therapy
Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P., & Tomlinson, I. M. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.08.007 · Cited by 345
Ke, W., Shao, K., Huang, R., Han, L., Liu, Y., Li, J., Kuang, Y., Ye, L., Lou, J., & Jiang, C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.049 · Cited by 337
Nanobodies and Their Potential Applications
Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., & Muyldermans, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.86 · Cited by 328
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
Nanobodies as novel agents for cancer therapy
Revets, H., De Baetselier, P., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Abulrob, A., Sprong, H., En Henegouwen, P. V. B., & Stanimirovic, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03463.x · Cited by 216
“injection, whether expressed in phage or purified (Muruganandam et al. 2002).”
BackgroundMethodSelf-citationHaqqani, A. S., Delaney, C. E., Tremblay, T.-L., Sodja, C., Sandhu, J. K., & Stanimirovic, D. B. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-4 · Cited by 198
“As shown in Table 2, several known receptors for BBB ‘Trojan horses’ were found in HBEC-EMVs, including TMEM30A, a putative antigen for the singledomain antibody, FC5, shown to transmigrate the BBB in vitro and in vivo [31-33](manuscript submitted).”
Self-citationProkaryotic expression of antibodies
Arbabi-Ghahroudi, M., Tanha, J., & MacKenzie, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-6193-1 · Cited by 191
“Molecules of this nature have great potential for the delivery of therapeutics across the blood brain barrier in the development of treatments for neurological diseases [61].”
BackgroundSelf-citationAdvanced Drug Delivery Systems That Target The Vascular Endothelium
Ding, B.-S. (2006) · Molecular Interventions · doi:10.1124/mi.6.2.7 · Cited by 182
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 163
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Metadata
- Authors
- Muruganandam, A., Tanha, J., Narang, S., & Stanimirovic, D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-12-28
- Volume
- 16
- Issue
- 2
- Pages
- 1-22
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2149218172
- Cited by
- 260
- References
- 28
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.